All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386,Apalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 13, 2021
Details:
Janssen may sponsor and conduct up to two Phase 1/2 studies evaluating the combination of EPI-7386 and apalutamide as well as the combination of EPI-7386 with abiraterone acetate plus prednisone in patients with mCRPC who have failed second-generation antiandrogen therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 12, 2021
Details:
ESSA Pharma is developing novel and proprietary therapies which include EPI-7386, for the treatment of patients with prostate cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2020
Details:
The studies highlight new information about EPI-7386. In an in vitro cellular thermal shift assay (CETSA), EPI-7386 was shown to physically interact with the both the full-length and the splice variant (AR-V7) form of the androgen receptor.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Abstract titled, EPI-7386, a potent N-terminal domain androgen receptor inhibitor, with a favorable preclinical safety and superior in vitro/in vivo profile, in clinical development for prostate cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
In an in vitro VCaP model, combination treatment of EPI-7386 with enzalutamide, apalutamide or darolutamide display broader and deeper inhibition of ARassociated transcriptional activity than higher doses of each single agent alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
The Phase 1 clinical trial will evaluate the safety and tolerability of EPI-7386 while additionally characterizing the pharmacokinetic, biological and anti-tumor effects of therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $39.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 28, 2020
Details:
ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
First patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer patients who failed standard of care treatments, including second generation anti-androgens.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386,Enzalutamide
Therapeutic Area: Oncology Product Name: EPI-7386
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The study highlighted full-length AR target engagement by EPI-7386, Its In vitro cellular gene expression analyses, Toxicology studies evaluating the safety profile of EPI-7386 and its starting clinical dose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPI-7386
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
In an oral poster presentation a more in-depth preclinical characterization of EPI-7386 including gene expression analyses and the toxicologic profile was presented.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
